Biotech Values

[microcapfun]

>>The AstraZeneca financed study, known as Jupiter, enrolled more than 15,000 basically healthy people with modest amounts of bad cholesterol (the average LDL level was 104), but high levels of a common marker of inflammation [CRP].

Researchers aimed to see whether Crestor lowered the risk of major cardiovascular events such as heart attack and stroke; the study was stopped early in March because of “unequivocal” benefits for patients who received the drug, but the full results have yet to be released [#msg-28053790].<<


Could it be that CRP had nothing to do with it - i.e. that Crestor's efficacy was due to simply lowering LDL to an even safer level? Many now advise reducing LDL to below 70. Only below about 70 does the amount of plaque actually decrease rather than increase more slowly.

At least that's what I read somewhere ...

micro